Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Jun 09, 2023 1:38pm
122 Views
Post# 35488842

RE:RE:RE:Twitter

RE:RE:RE:Twittergood comment  about the other potential products!  Not really  sure  what the game plan on those  is/was??  In reality  , Replicel cannot  bring these to market themselves  , they need a 'drug' manufacturer to partner with to do the testing  , manufacturing and  probably the  marketing with Replicel getting a cut.

It does not seem that they have persued companies to deal with the other products  -  or they have had no interest as  . like you say. we hear nothing about these products.  Also  , the  patents on these  have been around for quite a while and perhaps some of the companies have found newer and better approaches to address some of the issues covered by our other products.
I do not know how this tiff with  Shiseido would fator into discussions with other companies about other products?

Lets hope  we get a  good outcome  now  (at least enough to  return  your investment  and  we can hold Replicel  for any possible futures

GLTA
<< Previous
Bullboard Posts
Next >>